Trials / Completed

CompletedNCT00002388

A Study of 1592U89 in HIV-Infected Patients

A Study to Evaluate the Single-Dose and Steady-State Pharmacokinetics/Dynamics of 1592U89 and Its Active Moiety, 1144U88 5'-Triphosphate (1144U88-TP) Following Six Different Dosing Regimens of 1592U89 in HIV-1 Infected Subjects

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 48 (planned)

Sponsor: Glaxo Wellcome · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The purpose of this study is to see if it is safe to give 1592U89 to HIV-infected patients. This study also examines the effect 1592U89 has on plasma viral load (the level of HIV in the blood).

Detailed description

Cohorts of 8 patients are entered sequentially into 1 of 6 1592U89 dosing regimens. All patients receive 12 weeks of monotherapy during the initial 12-week treatment phase. On completion of the treatment phase, patients are offered continuation therapy with 1592U89 for a minimum of 12 weeks.

Conditions

HIV Infections

Interventions

Type	Name	Description
DRUG	Abacavir sulfate

Timeline

First posted: 2001-08-31
Last updated: 2005-06-24

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00002388. Inclusion in this directory is not an endorsement.